相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Self-Propelled Gemini-like LMWH-Scaffold Nanodrugs for Overall Tumor Microenvironment Manipulation via Macrophage Reprogramming and Vessel Normalization
Cheng Xu et al.
NANO LETTERS (2020)
Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis
Cheng-Liang Kuo et al.
CANCER LETTERS (2020)
Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1-mediated immunoescape via STING-IFN signaling and extracellular vesicles
An Ning Cheng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway
Kaiming Leng et al.
CELL DEATH & DISEASE (2019)
Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies
Yun-Chieh Sung et al.
NATURE NANOTECHNOLOGY (2019)
Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies
Behrad Darvishi et al.
LIFE SCIENCES (2019)
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Anushka Dongre et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells
Yusheng Lu et al.
PHARMACOLOGICAL RESEARCH (2019)
PA28γ acts as a dual regulator of IL-6 and CCL2 and contributes to tumor angiogenesis in oral squamous cell carcinoma
Sai Liu et al.
CANCER LETTERS (2018)
IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment
Tatiana A. Karakasheva et al.
CANCER RESEARCH (2018)
Vessels in the Storm: Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer
Adriano Angelucci et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Mitochondrial Lon sequesters and stabilizes p53 in the matrix to restrain apoptosis under oxidative stress via its chaperone activity
Ya-Ju Sung et al.
CELL DEATH & DISEASE (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
Adriana Albini et al.
FRONTIERS IN IMMUNOLOGY (2018)
USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation
Chih-Hao Lu et al.
ONCOGENE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Role of interleukin (IL)-17 and T-helper (Th)17 cells in cancer
Yang Song et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages
Kiavash Movahedi et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
Tumor-derived factors modulating dendritic cell function
Jinbao Zong et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
The Novel VEGF121-VEGF165 Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF165/Lon Signaling Through PI3K-AKT-mTOR Pathway
Jui-Ling Tsai et al.
CURRENT CANCER DRUG TARGETS (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma
Qi Huang et al.
SCIENTIFIC REPORTS (2016)
Combination Approaches with immune-Checkpoint Blockade in Cancer Therapy
Maarten Swart et al.
FRONTIERS IN ONCOLOGY (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mitochondrial Lon regulates apoptosis through the association with Hsp60-mtHsp70 complex
T-Y Kao et al.
CELL DEATH & DISEASE (2015)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis
Bob Yang et al.
MEDIATORS OF INFLAMMATION (2014)
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Michele De Palma et al.
CANCER CELL (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Alicia S. Chung et al.
NATURE MEDICINE (2013)
Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species
C-W Cheng et al.
CELL DEATH & DISEASE (2013)
Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Justin N. Bottsford-Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Inhibition of Dendritic Cell Maturation by the Tumor Microenvironment Correlates with the Survival of Colorectal Cancer Patients following Bevacizumab Treatment
Adriana J. Michielsen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Annamaria Rapisarda et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Regulatory dendritic cells: there is more than just immune activation
Susanne V. Schmidt et al.
FRONTIERS IN IMMUNOLOGY (2012)
Controlling escape from angiogenesis inhibitors
Barbara Sennino et al.
NATURE REVIEWS CANCER (2012)
Loss or Inhibition of Stromal-Derived PIGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia
Thomas Schmidt et al.
CANCER CELL (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
Sara Van de Veire et al.
CELL (2010)
Cancer Metastasis Is Accelerated through Immunosuppression during Snail-induced EMT of Cancer Cells
Chie Kudo-Saito et al.
CANCER CELL (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Dai Fukumura et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
分享论文
